IgA Half-Life Extension Solutions
Background Service Highlights Contact
Empowering Long-Acting IgA Therapeutics through Advanced Engineering
Immunoglobulin A (IgA) is increasingly recognized for its critical role in mucosal defense and its potential in next-generation immunotherapy. However, its naturally short serum half-life limits its therapeutic applications in systemic settings. At Creative Biolabs, we provide a suite of cutting-edge IgA Half-Life Extension Solutions designed to prolong the in vivo persistence of IgA antibodies without compromising their functional integrity. Through FcRn engagement strategies, glycan remodeling, and hybrid antibody construction, we deliver tailored approaches to enhance the pharmacokinetic profiles of your IgA candidates.
Our Tailored Strategies for IgA Half-Life Extension
IgA-FcRn Engagement based IgA Half-Life Extension Services
We introduce rational Fc mutations into the IgA Fc domain to enable pH-dependent binding to the neonatal Fc receptor (FcRn), facilitating recycling and serum half-life extension. Our approach ensures minimal structural perturbation and full preservation of antigen binding and FcαRI engagement.
Click the key word to learn more!
Glycoengineering based IgA Half-Life Extension Services
By modifying IgA glycan structures—either through glycoengineered host cells or enzymatic remodeling—we reduce interaction with clearance receptors such as ASGPR. This strategy effectively enhances IgA stability and circulation time while improving manufacturing consistency.
Click the key words to learn more!
IgA-IgG Hybrid Molecule Development Services
We construct chimeric IgA-IgG formats to merge the mucosal targeting ability of IgA with the systemic durability and FcRn affinity of IgG. Formats include Fc-fusion constructs, bispecifics, and customized IgA1/IgG1 hybrids for optimized dual-compartment efficacy.
Click the key words to learn more!
Comparative Table: Native IgA vs. Engineered IgA Variants
| Parameter | Native IgA | FcRn-Engineered IgA | Glycoengineered IgA | IgA-IgG Hybrid |
| FcRn Binding | Negligible | High (engineered pH-dependent interaction) | Moderate (indirect improvement via stability) | High (inherits from IgG Fc) |
| Ha-Life in Serum | ~5-6 days | Extended (comparable to IgG in optimized formats) | Extended (via reduced receptor-mediated clearance) | Extended (via FcRn recycling from IgG domain) |
| Mucosal Transport | High (via pIgR or SC binding) | Maintained | Maintained | Maintained or hybrid-dependent |
| Effector Function (e.g., FcαRI) | Fully active | Preserved (site-specific mutations avoid FcαRI sites) | Preserved (glycan remodeling doesn't affect Fc binding) | Dual (FcαRI + FcγRI/III depending on construct) |
| Manufacturing Complexity | Moderate (hinge-rich, glycosylated) | High (site-directed mutagenesis and screening required) | High (cell line engineering and profiling needed) | High (complex fusion formats and dual functionality) |
| Application Suitability | Mucosal infection, passive immunity | Systemic disease, long-term therapy | Autoimmunity, chronic mucosal inflammation | Dual-compartment targeting, oncology, long-acting delivery |
Why Choose Creative Biolabs
- Technology-Centric Advantages
FcRn Binding Optimization: Proprietary modeling and mutagenesis tools enable targeted Fc engineering for effective receptor engagement.
Glycan Precision Engineering: Access to stable cell lines (e.g., FUT8⁻/⁻, sialylation-enhanced CHO) and high-throughput glycan analysis platforms ensures glycoform consistency and half-life control.
Hybrid Format Expertise: Proven capability in designing and producing functional IgA-IgG hybrids tailored for mucosal and systemic co-engagement.
- Service-Centric Benefits
End-to-End Customization: From vector design to functional validation, we provide full-spectrum support adapted to your IgA subclass and indication.
In-House Analytical Capacity: State-of-the-art SPR, LC-MS, and bioassay platforms enable rapid QC, glycoprofiling, Fc functionality testing, and PK modeling.
Project Transparency & IP Respect: All projects are handled with strict confidentiality and dedicated project management to ensure milestone clarity and deliverable integrity.
Partner With Us
Whether you are advancing a mucosal immunotherapy candidate or re-engineering IgA for systemic delivery, Creative Biolabs is your ideal partner for extending IgA half-life through scientifically validated, regulatory-aware solutions. Our experienced scientists, GMP-adjacent platforms, and strong publication and project track record make us a trusted collaborator in antibody innovation.
Get in touch with our team today to explore customized strategies that bring your IgA therapeutic closer to clinical translation—with enhanced stability, efficacy, and patient benefit.
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
